Table 4.
Prognostic performance of liquid biopsy in PDAC.
| Tumor Stage | Nº Patients Total ctDNA + ctDNA- |
Results | Ref. |
|---|---|---|---|
| Resectable | 59 29 30 | RFS 8mo if pre-surgery ctDNA + vs. 19mo if ctDNA- (p < 0.01) | [135] |
| Resectable | 37 23 14 | RFS 10.3mo if pre-surgery ctDNA + vs. RFS not reached (p = 0.002) | [95] |
| Resectable | 34 14 * 20 * | ExoDNA KRAS MAF peak of ≥1% after treatment is associated with tumor progression | [97] |
| Advanced/metastatic | 104 50 54 | OS 6.5mo if ctDNA + vs. 19mo if ctDNA- (p < 0.001) | [154] |
| Advanced/metastatic | 55 42 13 | OS 2.5mo if ctDNA + with copy number gain vs. 5.5mo without copy number gain vs. 10.6mo if ctDNA- (p < 0.001) | [155] |
| Metastatic | 61 47 14 | OS 5.6mo if ctDNA + vs. 12.4mo if ctDNA- (p < 0.001) | [156] |
| Metastatic | 102 70 32 | OS 8.6mo if ctDNA + vs. 14.6mo if ctDNA- (p < 0.02) PFS 3.5mo if ctDNA + vs. 10.7mo if ctDNA- (p < 0.02) |
[97] |
| Any stage | 77 60 17 | KRAS MAF peak of <0.415% is associated with longer PFS and OS | [157] |
| Advanced/metastatic | 54 36 18 | Decrease in KRAS ctDNA levels during chemotherapy (d14) is an early indicator of response to treatment | [158] |
| Metastatic | 113 77 36 | Early change in ctDNA levels (d28) was correlated with ORR, PFS and OS | [159] |
| Advanced/metastatic | 38 17 21 | The dynamics of total cfDNA concentration correlated with tumor burden following chemotherapy | [117] |
| Metastatic | 188 65 123 | OS 4.7mo if ctDNA + vs. 6mo if ctDNA- (p = 0.015) | [160] |
ctDNA: circulating tumor DNA; MAF: mutant allele fraction; RFS: recurrence-free survival; OS: overall-survival; ORR: objective response rate; * ExoDNA.